Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
CRESTOR® (rosuvastatin calcium) may be an effective cholesterol management option for a variety of hyperlipidemic patients.
In this section, you can review results from comparative clinical trials in which CRESTOR was used as an adjunct to diet in African-American and Hispanic-American patients.
Initiation of CRESTOR therapy with 5 mg once daily should be considered for Asian patients.
For detailed clinical trial data, select the appropriate tab below. Click on the "+" and "—" signs to expand and collapse the clinical information.
‡Subject to eligibility. Restrictions apply. Click here for eligibility information.
LDL-C reductions vs atorvastatin in Hispanic-American adults with CHD, CHD risk equivalent, or a 10-year CHD risk score ≥10% and hypercholesterolemia2
Adapted from the STARSHIP Trial
NCEP ATP III LDL-C Goal Attainment <100 mg/dL in high-risk* Hispanic-American adults2,3
Adapted from the STARSHIP Trial
Lipitor is a registered trademark of Pfizer Inc.
You may report side effects related to AstraZeneca products by clicking here.